Featured Publications
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Anand A, Mathew S, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Collins K, Costi S, Iqbal S, Jha M, Krishnan K, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wilkinson S, Wolski K, Hu B. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal Of Medicine 2023, 388: 2315-2325. PMID: 37224232, DOI: 10.1056/nejmoa2302399.Peer-Reviewed Original ResearchConceptsTreatment-resistant major depressionPatient-reported qualityElectroconvulsive therapyMajor depressionECT groupKetamine groupTreatment phaseMusculoskeletal adverse effectsSubanesthetic intravenous ketamineWeeks of treatmentInitial treatment phaseIntravenous ketamineSecondary outcomesPrimary outcomeNoninferiority marginTrial groupECT clinicsNoninferiority trialPatientsComparative effectivenessKetamineClinical sitesAdverse effectsDepressionThree times
2020
Factors associated with health‐related quality of life in patients with cirrhosis: a systematic review
Rabiee A, Ximenes R, Nikayin S, Hickner A, Juthani P, Rosen RH, Garcia‐Tsao G. Factors associated with health‐related quality of life in patients with cirrhosis: a systematic review. Liver International 2020, 41: 6-15. PMID: 32998172, DOI: 10.1111/liv.14680.Peer-Reviewed Original ResearchMeSH KeywordsAdultCognitive DysfunctionHepatic EncephalopathyHumansLiver CirrhosisPatient Reported Outcome MeasuresQuality of LifeConceptsHealth-related qualityPoor HRQOLMuscle crampsHepatic encephalopathyPoor sleepSystematic reviewPoor health-related qualityPatient-reported outcomesPoor social supportPatient-centered careFull-text screeningAdult patientsPoor HRQoL.Cirrhosis etiologyHRQoLCirrhosisGeneric instrumentsEligibility criteriaCognitive impairmentPatientsMajority of studiesIdentified factorsCrampsDemographic factorsFrailty